You are here

Engineering cells for concurrent protein drug biosynthesis and polysialylation

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43GM109504-01
Agency Tracking Number: R43GM109504
Amount: $148,202.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIGMS
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1938 Harney St
LARAMIE, WY 82072-3037
United States
DUNS: 968784103
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 CHRISTOPH GEISLER
 (307) 340-1616
 christophgeisler@gmail.com
Business Contact
 DONALD JARVIS
Phone: (307) 760-8194
Email: DLJarvis@uwyo.edu
Research Institution
 Stub
Abstract

Project Summary / Abstract Therapeutic proteins, or biologics, represent a 100 billion market that includes drugs such as antibodies, hormones, and many others. The clinical efficacy of biologics is critically determined by their circulating half-lives.Hence, various methods have been developed to increase their circulating half-lives by reducing clearance rates. This is commonly achieved by chemically conjugating biologics with biocompatible polymers in vitro. However, chemical conjugation is expensive,complicated, and often results in substantial losses of specific activity as well as a heterogeneous product mixture. These serious drawbacks have created a demand for a technology that can add biocompatible polymers to biologics without in vitro chemistry. To meet this demand, GlycoBac proposes a new, innovative method to add polysialic acid to biologics during their biosynthesis. Polysialic acid is (PSA) naturally found in the human body, and is a fully biocompatible, biodegradable and non-immunogenic

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government